What were the results of the Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial?
The WARCEF trial randomized 2305 patients with reduced left ventricular ejection fraction and sinus rhythm to warfarin or aspirin and followed them up for up to 6 years. There was no difference in the primary composite outcome of ischemic stroke, ICH, or death resulting from any cause (HR, 0.93; 95% CI, 0.79 1.10), but there was a significant reduction in the rate of ischemic stroke with warfarin compared with aspirin (0.72 versus 1.36 events per 100 patient-years; HR, 0.52; 95% CI, 0.33 0.82). The rate of major hemorrhage, however, was greater in the warfarin than in the aspirin group.